C
hronic childhood lead exposure is linked to significant long-term consequences, including neurologic symptoms, behavioral disorders, cognitive delays, and lower educational attainment. 1 Sources of exposure include lead-based paint, contaminated water and soil, and imported goods. 2 Exposed children may be asymptomatic; therefore, physicians use verbal risk assessments and blood lead level (BLL) tests to determine exposure severity and appropriate treatment. 2 The Centers for Disease
Control and Prevention acknowledges that there is no safe level of lead exposure but currently classifies 5 micrograms per deciliter or more of lead in the blood as "elevated."
2 California guidelines suggest physicians consider public health case management referrals for BLLs of 10 micrograms per deciliter or more and treat BLLs of 45 micrograms per deciliter or more as urgent medical conditions. 3 Through nationwide abatement policies such as the prohibition of leaded gasoline and paint, the prevalence of elevated BLLs has decreased across the United States from 7.6% in 1997 to 0.5% in 2015. 4 In California, BLL screening is required for children enrolled in Medicaid and other public assistance programs and children deemed at risk because they live in a home built before 1978. 3 
METHODS
At the request of the California State Legislature, the California Health Benefits Review Program (CHBRP) conducted a comprehensive analysis of AB 1316. 9 CHBRP includes University of California faculty who provide the legislature with independent analyses of health insurancerelated bill impacts. CHBRP used 3 information sources for this analysis: a systematic literature review, a survey of California's largest health insurers, and utilization and cost data analyzed by contracted actuaries using Truven Health Analytics' 2014 to 2015 MarketScan claims database. The analysis was limited to state-regulated health insurance and excluded government-funded plans (e.g., Medicaid). 
RESULTS
The most recent US Preventive Services Task Force Guidelines recommend against universal BLL screening and conclude that there is insufficient evidence for or against screening children at increased risk. 10 In addition, CHBRP found no recent literature that compared the effectiveness of universal versus targeted lead exposure screening. 9 One 1997 study used mathematical simulations and found that at or above a 14% prevalence of elevated BLLs among those aged 1 year, the benefits of universal screening outweigh the costs. 11 In addition to higher testing costs, false positives and screening-related anxiety were identified as potential harms of universal screening.
Approximately 1 016 435 California children aged 0 to 72 months had health insurance subject to AB 1316, with all plans covering BLL screening. However, AB 1316 changed the standard of care to require universal BLL screening. Therefore, in the first year after AB 1316 implementation, it is estimated that 252 754 additional children would receive a BLL test, representing a 273% increase (Table 1 ). CHBRP also estimates that an increase in utilization of BLL tests would increase total net health care expenditures in the state by $6.2 million in the first year, which would result in a 0.0043% average premium increase paid by enrollees or employers.
On the basis of California's 2012 surveillance of elevated child BLLs (1.89% with BLLs ‡ 5 mg/dL and 0.26% with BLLs ‡ 10 mg/dL), the additional 252 754 screenings attributable to AB 1316 conducted 1 year after the mandate may detect elevated BLLs ( ‡ 5 mg/dL) among an estimated 0.47% (4777) children with health insurance subject to AB 1316. Additionally, 0.06% (657) children may be found to have BLLs of 10 micrograms per deciliter more, the level at which California physicians may consider referrals for public health case management.
DISCUSSION
We found that universal screening in California may lead to an estimated additional quarter million children screened in the first year and nearly 5000 children identified with BLL of 5 micrograms per deciliter or more. In subsequent years, the number of new screenings may be smaller as the backlog of unscreened children diminishes. A minimal increase in health insurance premiums would ensure coverage for these screenings.
In April 2017, this analysis was submitted to the California Assembly Health Committee for use in their deliberations on AB 1316. Opposition to the bill was registered by the California Medical Association and the American Academy of Pediatrics, which noted that the bill's universal screening requirement contradicts current medical literature related to lead screening. 12 The revised bill requires targeted screening of high-risk children by expanding the criteria for determining risk, including factors such as time spent in a home, a school, or other building built before 1978; proximity to a former lead or steel smelter or industrial facility; and proximity to freeways or other heavily traveled roadways. The governor signed this version of the bill into law on October 5, 2017. Because of the shift in requirements from universal to expanded targeted screening, it stands to reason that the amended bill would lead to fewer additional screenings and subsequently fewer newly detected cases of child lead exposure than are estimated here. However, because BLL screening has a false positive rate of 3% to 9% of tests, 9 the amended bill's expanded targeted screening would likely produce a lower number of false positives than would universal screening.
PUBLIC HEALTH IMPLICATIONS
It is important to consider this policy decision in the broader context of lead screening nationally. Amid the declining prevalence of 2 With legislation requiring universal screening enacted or under consideration in many states, these findings are important for legislators and advocates to consider in weighing the costs and benefits of such proposals. Although the costs of universal screening are not significant, the evidence to support a universal screening approach is limited and is not supported by prominent medical professional groups. Yet, the previous methodology employed in California was also criticized for requiring only 1 question regarding age of housing as a mechanism for identifying those at high risk.
By passing the amended version of AB 1316, California was able to expand targeted screening to identify additional children at higher risk for lead poisoning on the basis of California-specific risk factors, while mitigating potential harms of universal screening such as an increase in false positive tests and health care costs. In addition, future studies should explore the relationship between universal screening policies and the corresponding identification of additional children with elevated BLLs. Data sharing of rates of identified children with elevated BLLs and collection of zip codes when reporting elevated BLLs (as required per AB 1316) between state health departments and researchers could help in the effort to identify the most effective policies for elevated BLL identification. 
